Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179010 · ClinicalTrials.gov registry record · Phase 1
AMP as a Better Delivery System of Adenosine
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00179010 is a Phase 1 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 13 participants.
The verdict
NCT00179010, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenosine we give by vein or in the artery actually reaches the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the forearm artery while we measure how much adenosine reaches the forearm tissue.
Interventions
- DRUG Adenosine
- DRUG Adenosine Mono Phosphate (AMP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2003-10 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179010
The ClinicalTrials.gov registry entry for NCT00179010 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adenosine is the first listed.
NCT00179010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179010 about?
NCT00179010 is a clinical study titled "AMP as a Better Delivery System of Adenosine". Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenos...
What is the current status of trial NCT00179010?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2003-10. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00179010?
The interventions under investigation include: Adenosine (DRUG), Adenosine Mono Phosphate (AMP) (DRUG).
Who is sponsoring clinical trial NCT00179010?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.